share_log

Verve Therapeutics (NASDAQ:VERV) Vs. KemPharm (NASDAQ:KMPH) Head-To-Head Review

Verve Therapeutics (NASDAQ:VERV) Vs. KemPharm (NASDAQ:KMPH) Head-To-Head Review

神韻治療 (納斯達克:活性) Vs.醫藥 (納斯達克:KMPH) 頭對頭審查
Defense World ·  2023/02/28 15:12

KemPharm (NASDAQ:KMPH – Get Rating) and Verve Therapeutics (NASDAQ:VERV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

肯德基(納斯達克:kmph-GET評級)和維維治療(納斯達克:VERV-GET評級)都是小盤醫療公司,但哪隻股票更優越?我們將根據這兩家公司的估值、機構所有權、收益、風險、盈利能力、分析師建議和股息等方面的實力進行比較。

Analyst Recommendations

分析師建議

This is a summary of recent ratings and price targets for KemPharm and Verve Therapeutics, as provided by MarketBeat.com.

這是由MarketBeat.com提供的KemPharm和Verve Treateutics最近的評級和目標價摘要。

Get
到達
KemPharm
健美藥業
alerts:
警報:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KemPharm 0 0 4 0 3.00
Verve Therapeutics 1 2 3 0 2.33
銷售評級 保持評級 購買評級 強勁的買入評級 評級分數
健美藥業 0 0 4 0 3.00
Verve治療公司 1 2 3 0 2.33

KemPharm currently has a consensus price target of $17.25, indicating a potential upside of 195.88%. Verve Therapeutics has a consensus price target of $40.00, indicating a potential upside of 111.30%. Given KemPharm's stronger consensus rating and higher possible upside, equities research analysts plainly believe KemPharm is more favorable than Verve Therapeutics.

KemPharm目前的共識目標價為17.25美元,表明潛在上行空間為195.88%。Verve治療公司的共識目標價為40美元,表明潛在漲幅為111.30。考慮到KemPharm更強的共識評級和更高的可能上行空間,股票研究分析師顯然認為KemPharm比Verve治療公司更有利。

Profitability

盈利能力

This table compares KemPharm and Verve Therapeutics' net margins, return on equity and return on assets.

此表比較了KemPharm和Verve Treeutics的淨利潤率、股本回報率和資產回報率。

Net Margins Return on Equity Return on Assets
KemPharm -328.56% -16.12% -14.17%
Verve Therapeutics N/A -38.52% -34.12%
淨利潤率 股本回報率 資產回報率
健美藥業 -328.56% -16.12% -14.17%
Verve治療公司 不適用 -38.52% -34.12%

Earnings and Valuation

收益和估值

This table compares KemPharm and Verve Therapeutics' revenue, earnings per share and valuation.

此表比較了KemPharm和Verve Treateutics的收入、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
KemPharm $28.65 million 7.02 -$8.56 million N/A N/A
Verve Therapeutics $929,000.00 1,255.29 -$120.31 million ($2.90) -6.53
總收入 價格/銷售額比 淨收入 每股收益 市盈率
健美藥業 2,865萬美元 7.02 -856萬元 不適用 不適用
Verve治療公司 $929,000.00 1,255.29 -1.2031億美元 ($2.90) -6.53

KemPharm has higher revenue and earnings than Verve Therapeutics.

KemPharm的收入和收益比Verve治療公司高。

Volatility and Risk

波動性和風險

KemPharm has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

KemPharm的貝塔係數為2.16,表明其股價的波動性比標準普爾500指數高出116%。相比之下,Verve Treateutics的貝塔係數為1.54,這表明其股價的波動性比標準普爾500指數高54%。

Institutional and Insider Ownership

機構和內部人持股

19.4% of KemPharm shares are held by institutional investors. Comparatively, 98.5% of Verve Therapeutics shares are held by institutional investors. 1.1% of KemPharm shares are held by insiders. Comparatively, 26.4% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

金藥19.4%的股份由機構投資者持有。相比之下,Verve Treateutics 98.5%的股份由機構投資者持有。KemPharm 1.1%的股份由內部人士持有。相比之下,Verve Treateutics 26.4%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一隻股票的長期表現將好於大盤。

Summary

摘要

KemPharm beats Verve Therapeutics on 8 of the 12 factors compared between the two stocks.

在兩隻股票之間的12個因素中,KemPharm在8個因素上擊敗了Verve Treateutics。

About KemPharm

關於肯德基製藥公司

(Get Rating)

(獲取評級)

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

凱姆製藥公司是一家臨牀階段的專業製藥公司,致力於專利前體藥物的發現和開發。它專注於通過其名為配體激活療法的平臺技術來治療嚴重的疾病,如注意力缺陷多動障礙、疼痛和其他中樞神經系統疾病。該公司由克里斯托·M·M·米克爾和特拉維斯·C·米克爾於2006年10月30日創立,總部設在佛羅裏達州的慶典。

About Verve Therapeutics

關於Verve Treateutics

(Get Rating)

(獲取評級)

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve治療公司是一家基因藥物公司,致力於為患者開發治療心血管疾病的基因編輯藥物。它的主要候選產品是VERVE-101,這是一種單療程基因編輯療法,可以永久關閉肝臟中的PCSK9基因。該公司還參與了Angptl3程序的開發,以永久關閉肝臟中的Angptl3基因。它與比姆治療公司有一項合作和許可協議;與Acuitas治療公司有一項開發和選擇協議;與布羅德研究所和哈佛學院的總裁和研究員有一份CAS9許可協議。該公司前身為Endcadia,Inc.,2019年1月更名為Verve Treateutics,Inc.。Verve治療公司成立於2018年,總部設在馬薩諸塞州劍橋市。

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

接受KemPharm日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對肯德基製藥及相關公司評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論